Xisomab 3G3 - Aronora

Drug Profile

Xisomab 3G3 - Aronora

Alternative Names: AB 022; AB 023; Mab 14E11 - Aronora; XISOMAB; Xisomab3G3

Latest Information Update: 09 Apr 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Oregon Health & Science University
  • Developer Aronora
  • Class Antiseptics; Antithrombotics; Monoclonal antibodies; Recombinant proteins
  • Mechanism of Action Factor XI inhibitors; Factor XII inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Thrombosis
  • Preclinical Cardiovascular disorders; Sepsis

Most Recent Events

  • 10 Aug 2018 Aronora plans a phase II trial for Thrombosis (in patients with end-stage renal disease) in October 2018 (NCT03612856)
  • 16 Jan 2018 Aronora completes a phase I trial in Thrombosis (In volunteers) in USA (IV) (NCT03097341)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top